1,296 results on '"Westervelt, Peter"'
Search Results
102. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome
103. Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML
104. Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia
105. Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia
106. Limited Sequence Heterogeneity Among Biologically Distinct Human Immunodeficiency Virus Type 1 Isolates from Individuals Involved in a Clustered Infectious Outbreak
107. Identification of a Determinant within the Human Immunodeficiency Virus 1 Surface Envelope Glycoprotein Critical for Productive Infection of Primary Monocytes
108. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
109. Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission
110. Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation
111. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction
112. DNMT3A mutations in acute myeloid leukemia
113. A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML
114. Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers
115. Genome-wide analysis of focal DNA hypermethylation in IDH-mutant AML samples
116. A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102
117. Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic
118. A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes
119. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
120. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia
121. Clinical response of myelodysplastic syndromes patients to treatment with coenzyme Q10
122. Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
123. Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma
124. Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML
125. A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102
126. IFNL4 and donor selection for matched unrelated donor haematopoietic stem-cell transplantation
127. 136 - Mgta-117, an Anti-CD117-Amanitin Antibody-Drug Conjugate, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics, and Pharmacodynamics Initial Findings from a Phase 1/2 Study
128. Comparative Evaluation of Single Fixed Dosing and Weight-Based Dosing of Rasburicase for Tumor Lysis Syndrome
129. Dose Intensification of Daunorubicin and Cytarabine During Treatment of Adult Acute Lymphoblastic Leukemia: Results of Cancer and Leukemia Group B Study 19802
130. Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors
131. Clonal Architecture of Secondary Acute Myeloid Leukemia
132. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A phase I study
133. Whole-Genome Sequencing and Acute Promyelocytic Leukemia—Reply
134. Use of Whole-Genome Sequencing to Diagnose a Cryptic Fusion Oncogene
135. The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced‐intensity hematopoietic peripheral blood cell transplant – a retrospective study
136. Role of Transplant Conditioning Regimen Intensity in High-Risk Acute Myelogenous Leukemia
137. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020
138. Ruxolitinib for steroid‐refractory acute graft‐versus‐host disease
139. Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia
140. Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide
141. Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
142. Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS
143. The Molecular Basis of Long First Remissions in Normal Karyotype AML Patients
144. Use of Cytomegalovirus Intravenous Immune Globulin for the Adjunctive Treatment of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
145. A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
146. Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
147. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes
148. Assessment of an Alternative Meropenem Dosing Strategy Compared with Imipenem-Cilastatin or Traditional Meropenem Dosing After Cefepime Failure or Intolerance in Adults with Neutropenic Fever
149. A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid-Refractory Acute Graft-versus-Host Disease
150. Sars-Cov-2 Vaccination in the First Year after Hematopoietic Cell Transplant or Chimeric Antigen Receptor T Cell Therapy: A CIBMTR and BMT CTN Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.